Scott R . Plotkin, M.D., Ph.D., Anat O. Stemmer-Rachamimov, M.D., Fred G. Barker, II, M.D., Chris Halpin, Ph.D., Timothy P. Padera, Ph.D., Alex Tyrrell, Ph.D., A. Gregory Sorensen, M.D., Rakesh K. Jain, Ph.D., and Emmanuelle di Tomaso, Ph.D.: Hearing Improvement after Bevacizumab in Sufferers with Neurofibromatosis Type 2 Neurofibromatosis type 2 is a dominantly inherited genetic condition with a birth prevalence of 1 1 in 25,000.1 Bilateral vestibular schwannomas , which are benign tumors made up of neoplastic Schwann cells that arise from the eighth cranial nerve, are the hallmark of neurofibromatosis 2. These tumors cause progressive hearing loss generally in most individuals with neurofibromatosis type 2, who lose most functional hearing during early adulthood or middle age commonly.

We corrected for elements that might have got influenced this decision, such as age at analysis, tumor size, and tumor quality. To eliminate axillary lymph-node dissection as a confounder, we performed an additional analysis of the node-unfavorable, no-adjuvant-therapy cohort versus the node-positive, no-adjuvant-therapy cohort with this adjustable contained in the model, with fundamentally the same outcome . No summary was possible regarding the aftereffect of axillary lymph-node dissection on disease-free survival and the recurrence rate in the axilla. To address that question, analyses have to be based on the sentinel-node status of the final nodal status instead..